Virtual Library

Start Your Search

Marcelo Garrido



Author of

  • +

    P2.03 - Biology (Not CME Accredited Session) (ID 952)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.03-01 - Prevalence of EGFR Alterations in Chilean Lung Cancer Patients: A Retrospective Study (ID 11946)

      16:45 - 18:00  |  Author(s): Marcelo Garrido

      • Abstract
      • Slides

      Background

      Recently, several countries in Latin America (LA) have entered into an epidemiological shift, switching the burden of disease from infectious to chronic non-transmittable disorders. In fact, many studies anticipate that Lung Cancer (LC) will soon emerge as the first cause of mortality in the region, possibly over the next decade. In Chile, LC is currently the second leading cause of cancer death and responsible for >2,500 deaths every year. Epidemiological data from Chilean LC patients is scarce and scattered. On the other hand, Tyrosine Kinase Inhibitor (TKI) drugs have been successfully used in a subset of LC patients that harbor alterations in the Epidermal Growth Factor Receptor (EGFR) gene. Here, we aimed to quantify the prevalence of EGFR alterations in the Chilean population

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We performed a retrospective study that involved 1,405 biopsies from 1,385 Chilean LC patients. Then we selected patients with EGFR alterations and retrieve clinical data from these patients including age, gender, histological type, smoking habits and type of EGFR alteration. We also analyzed overall survival (OS) rates

      4c3880bb027f159e801041b1021e88e8 Result

      We found that 300 out of 1,385 (21.7%) had clinically relevant EGFR alterations. Within this group median age at diagnosis was 65 yr. As expected, most patients were female (64%), and classified as Non-Small Cell Lung Cancer adenocarcinomas (94.5%). Also in patients with EGFR alterations, the majority were either non-smokers or light smokers (93.1%). Regarding the type of EGFR alterations the most prevalent was the exon 19 deletions (50.6%) followed by Leucine-to Arginine 858 (L858R, 28.9%). Further analyses indicated that OS within this group was 15 months. Also, information clinical follow-up and TKI treatment was available for 87 patients. As expected the use of TKIs in these patients significantly improved OS

      8eea62084ca7e541d918e823422bd82e Conclusion

      The prevalence of EGFR alterations in the Chilean population is 21.7%, a value between the Caucasian and Asian population, 18.6% and 57.1% respectively. This value is also comparable to other reports from countries within LA such as Argentina (14.4%), Uruguay (18.3%), Colombia (24.7%) and Peru (37%). Similarly, OS was 15 months and the most frequent EGFR reported alteration was exon 19 deletions. Finally, the use of TKIs in these patients significantly improves OS.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.